Search | Page 2 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Optimizing the use of hypomethylating agents in myelodysplastic syndromes: Selecting the candidate, predicting the response, and enhancing the activity

    ... and mortality. The hypomethylating agents (HMAs) azacitidine and decitabine are approved for use in the United ... of MDS or acute myeloid leukemia (AML) and, in the case of azacitidine, prolong survival in higher-risk patients. Neither is curative, ...

    Research Article last updated 10/02/2017 - 10:03am.

  2. Efficacy, safety, and pharmacokinetics of subcutaneous azacitidine in Taiwanese patients with higher-risk myelodysplastic syndromes

    ... AIM: Clinical and pharmacokinetic effects of azacitidine in higher-risk myelodysplastic syndromes were ... of drug-metabolizing enzymes, it is important to evaluate azacitidine in populations expected to use the drug. METHODS: In this ...

    Research Article last updated 02/03/2017 - 10:05am.

  3. A call for action: Increasing enrollment of untreated patients with higher-risk myelodysplastic syndromes in first-line clinical trials.

    ... and quality of life and, in the case of azacitidine , prolonged survival in a large randomized trial. However, ... Furthermore, the 24-month median survival observed with azacitidine in the landmark AZA-001 trial has not been replicated in population-based studies or in other clinical trials using azacitidine monotherapy arms. Herein, we critically review the accumulating ...

    Research Article last updated 09/11/2017 - 9:04am.

  4. Foundation Update - April 2016

    ... erythropoietin (Procrit®), G-CSF, (Neupogen®), azacitidine , (Vidaza®) and deferoxamine (Desferal®). My hemoglobin ... far this year which is more than usual for me, and my last azacitidine (Vidaza®) treatment in June didn't seem to have much benefit. ...

    Article last updated 10/09/2017 - 2:57pm.

  5. Patient Trusts Her Instincts in Finding the Right Treatment

    ... my doctor at Ochsner agreed that the next step should be azacitidine (Vidaza®). I was scheduled to begin the azacytidine by ... I still had an uneasy feeling about the upcoming azacitidine treatment  -- that it would be only a crutch and not a cure. I ...

    Patient Chronicle last updated 05/10/2018 - 11:01am.

  6. Early treatment initiation in lower-risk myelodysplastic syndromes produces an earlier and higher rate of transfusion independence

    ... (2006-2012) to estimate the impact of DMT-initiation ( azacitidine , decitabine , or lenalidomide ) timing (≤ 3 ...

    Research Article last updated 09/13/2017 - 8:58am.

  7. Phase 2, randomized, double-blind study of pracinostat in combination with azacitidine in patients with untreated, higher risk myelodysplastic syndromes

    ... activity in patients with MDS and in vitro synergy with azacitidine . METHODS: A phase 2 randomized, placebo -controlled clinical trial of azacitidine and pracinostat was conducted in patients who had International ...

    Research Article last updated 02/03/2017 - 11:12am.

  8. Safety and efficacy of azacitidine in elderly patients with intermediate to high-risk myelodysplastic syndromes

    ... or transformation to acute myeloid leukemia (AML). Azacitidine was the first DNA hypomethylating agent approved by the United ... survival is independent of achieving a complete remission. Azacitidine has been used in older patients with both clinical and ...

    Research Article last updated 02/01/2017 - 8:17am.

  9. Bone marrow hypocellularity does not affect tolerance or efficacy of azacitidine in patients with higher-risk myelodysplastic syndromes

    ... The efficacy and tolerance of azacitidine in higher-risk myelodysplasia with hypocellular ... the overall survival (OS) advantage demonstrated with azacitidine versus conventional care regimens (CCR). Baseline BM biopsies of ...

    Research Article last updated 02/04/2014 - 1:32pm.

  10. Use of azacitidine for myelodysplastic syndromes: controversial issues and practical recommendations.

    ... Azacitidine is recommended for patients with higher-risk ... to other therapies. However, standard treatment with azacitidine has not been optimized and many issues about the use of azacitidine ...

    Research Article last updated 07/09/2013 - 3:03pm.